Form 8-K - Current report:
SEC Accession No. 0001694665-23-000100
Filing Date
2023-06-29
Accepted
2023-06-29 17:10:41
Documents
14
Period of Report
2023-06-29
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evlo-20230629.htm   iXBRL 8-K 37842
2 EX-3.1 evlo-charteramendmentxreve.htm EX-3.1 10739
6 evlo-20230629_g1.jpg GRAPHIC 7885
  Complete submission text file 0001694665-23-000100.txt   212430

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evlo-20230629.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evlo-20230629_lab.xml EX-101.LAB 25834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evlo-20230629_pre.xml EX-101.PRE 13584
8 EXTRACTED XBRL INSTANCE DOCUMENT evlo-20230629_htm.xml XML 4752
Mailing Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 500 CAMBRIDGE MA 02139 617-577-0300
Evelo Biosciences, Inc. (Filer) CIK: 0001694665 (see all company filings)

EIN.: 465594527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38473 | Film No.: 231058394
SIC: 2834 Pharmaceutical Preparations